Manulife (Manufacturers Life Insurance)
RLMD icon

Manulife (Manufacturers Life Insurance)’s Relmada Therapeutics RLMD Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20,343
Closed -$61K – 3011
2023
Q3 		$61K Hold
20,343
– – ﹤0.01% 2929
2023
Q2 		$50K Sell
20,343
-4,694
-19% -$13K ﹤0.01% 2949
2023
Q1 		$56.6K Hold
25,037
– – ﹤0.01% 2844
2022
Q4 		$88.6K Sell
25,037
-5,393
-18% -$47.4K ﹤0.01% 2823
2022
Q3 		$1.11M Sell
30,430
-275
-0.9% -$7.62K ﹤0.01% 1562
2022
Q2 		$590K Buy
30,705
+16,499
+116% +$360K ﹤0.01% 1933
2022
Q1 		$379K Buy
+14,206
New +$294K ﹤0.01% 2360
2021
Q4 		– Sell
-8,407
Closed -$220K – 3169
2021
Q3 		$220K Sell
8,407
-413
-5% -$11.1K ﹤0.01% 2918
2021
Q2 		$282K Buy
8,820
+513
+6% +$17.8K ﹤0.01% 2857
2021
Q1 		$292K Sell
8,307
-473
-5% -$16.5K ﹤0.01% 2638
2020
Q4 		$282K Buy
8,780
+658
+8% +$22.6K ﹤0.01% 2556
2020
Q3 		$306K Hold
8,122
– – ﹤0.01% 2282
2020
Q2 		$350K Buy
+8,122
New +$343K ﹤0.01% 2147

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s RLMD Position: Q4 2023 in Review

Manulife (Manufacturers Life Insurance) sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 20,343 shares — an estimated $61K sold.

Manulife (Manufacturers Life Insurance) first reported a position in RLMD in Q2 2020 and held it in 13 quarters. The position peaked at $1.11M in Q3 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Manulife (Manufacturers Life Insurance) reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 20,343 Relmada Therapeutics shares in Q4 2023, an estimated $61K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Relmada Therapeutics in Q2 2020 and held it in 13 quarters.
  • Manulife (Manufacturers Life Insurance)'s Relmada Therapeutics position peaked at $1.11M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q4 2023, filed 13 Feb 2024.